India · Delayed Price · Currency is INR Sanofi India Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 saw strong double-digit growth in the diabetes segment, margin expansion, and a 34% increase in cash reserves. Partnership and export businesses faced headwinds, but strategic transformation and public sector expansion supported overall performance.
Fiscal Year 2025
-
Transformation year saw flat domestic sales but 1% profit growth, with diabetes segment leading and partnership sales volatile due to inventory effects. Dividend per share proposed at INR 123, up 5%. Focus remains on diabetes, insulin, and operational efficiency.
-
Business transformation focused on diabetes and insulin drove margin expansion and operational efficiency, with double-digit profit growth and improved OpEx ratios. Export sales declined due to site divestment but are being offset by new markets. Interim dividend of INR 75 per share declared.